Endometrial Cancer Molecular Classification and Why Missed Testing Can Matter

Endometrial cancer molecular classification examines features of a tumor that can affect its risk of returning and its response to treatment. Two cancers with the same appearance under a microscope can belong to different molecular groups, with different implications for care.

The practical question is whether the pathology workup gave your oncology team the information needed to make an appropriate treatment plan.

A missing test or misunderstood result can warrant review, but it does not, by itself, establish medical malpractice.

The Four Molecular Subtypes of Endometrial Cancer

The Cancer Genome Atlas identified four genomic groups in its 2013 study of endometrial carcinoma. Practical clinical classifiers subsequently made similar groupings possible without repeating that study’s extensive research testing.

The Society of Gynecologic Oncology’s clinical practice statement on molecular testing describes the four clinical groups and recommends basic molecular classification, including assessment of mismatch repair status, for all endometrial cancers.

Molecular group	What the result identifies	Why it matters
POLE-mutated, or POLEmut	A qualifying pathogenic change in the DNA proofreading region of the POLE gene	Generally associated with favorable outcomes. It can support less treatment after surgery in selected early-stage cancers.
Mismatch repair deficient, or MMRd	Loss of function in a system that repairs DNA copying errors	Can inform immunotherapy decisions and prompt evaluation for Lynch syndrome.
p53-abnormal, or p53abn	An abnormal p53 protein staining pattern, usually reflecting an alteration in TP53	Generally associated with a less favorable outlook and can affect recommendations for additional treatment.
No specific molecular profile, or NSMP	No qualifying POLE mutation, retained mismatch repair function, and a normal p53 pattern within the classification workup	A varied group. Other pathology findings and biomarkers remain important when assessing risk and treatment.

These are group-level associations, not predictions of an individual person’s outcome. An NSMP result does not mean that the tumor has no genetic changes or that all additional biomarker testing is unnecessary.

How POLE, MMR, and p53 Testing Works

Molecular classification commonly combines tissue stains with DNA testing. The precise workflow can differ between laboratories.

Mismatch repair testing often uses immunohistochemistry, or IHC. This technique stains tissue to assess proteins such as MLH1, PMS2, MSH2, and MSH6. Loss of a protein can indicate that the tumor’s DNA repair system is not working properly.

p53 testing commonly uses IHC to assess the protein’s staining pattern. Pathologists interpret abnormal patterns rather than treating any positive staining as an abnormal result.

POLE testing examines tumor DNA for relevant gene changes. A variant of uncertain significance is not equivalent to a qualifying pathogenic mutation and should not automatically place a tumor in the favorable POLEmut group.

Results may appear in an addendum issued after the original pathology report. Ask for the complete report and subsequent addenda, rather than assuming the first page contains every completed test.

How Molecular Results Can Change Treatment

Molecular information can influence both the amount of treatment recommended and which treatments are considered. It must be interpreted with the cancer’s stage, other risk features, previous treatment, and your health.

Treatment After Surgery

For high-risk disease, molecular analyses of the PORTEC-3 trial support the importance of p53 status. The 2025 long-term PORTEC-3 report found benefits from combined chemotherapy and radiation compared with radiation alone, with the most clinically relevant benefit suggested in p53-abnormal cancers.

Its molecular analysis was post hoc, meaning investigators examined subgroups within the trial population afterward.

That evidence does not establish that every p53-abnormal tumor requires the same treatment. The trial studied high-risk cancers, and treatment recommendations must match the patient’s actual clinical setting.

Immunotherapy for Advanced or Recurrent Disease

Mismatch repair status is important for immunotherapy, but immunotherapy is not limited to MMRd endometrial cancer.

In June 2024, the FDA approved pembrolizumab with carboplatin and paclitaxel, followed by pembrolizumab alone, for adults with primary advanced or recurrent endometrial carcinoma.

In August 2024, it expanded dostarlimab with chemotherapy, followed by dostarlimab alone, to the same broad disease setting without restricting that indication to MMRd tumors.

The relevant biomarker requirements differ between regimens and treatment settings. Your oncologist should explain which results affect the particular option being discussed, rather than treating “MMR proficient” as a blanket reason to exclude immunotherapy.

Our overview of endometrial cancer treatment options explains the broader treatment categories. Molecular classification helps refine those decisions.

What the 2023 FIGO Staging Changes Mean

The International Federation of Gynecology and Obstetrics, known as FIGO, incorporated molecular findings into its 2023 endometrial cancer staging framework.

For tumors otherwise classified within stages I or II, qualifying POLEmut disease confined to the uterine body or extending into the cervix can be designated stage IAm_POLEmut.

A p53-abnormal cancer confined to the uterine body with invasion into its muscle, with or without cervical invasion, can be designated stage IICm_p53abn.

MMRd and NSMP findings do not change the early-stage category. Molecular findings also do not change the anatomical stage category for stage III or IV disease, although they should be recorded when known.

A changed stage label after molecular review does not necessarily mean the cancer physically spread between reports. Ask which staging system was used and which finding changed the designation.

Questions to Ask Your Oncology Team

Ask for explanations tied to your own report.

• Has my tumor received a molecular classification, and where is the final result documented?

• Were MMR, p53, and POLE assessed? If any test was omitted, would its result change my care?

• Are any findings uncertain, conflicting, or limited by the amount of tumor tissue?

• Does my result change the stage designation or recommendation for treatment after surgery?

• Do I need genetic counseling, additional biomarkers, or a specialist pathology review?

If you are still being evaluated for symptoms, do not wait for a molecular-testing discussion to seek care. Molecular classification follows identification of a tumor.

Our guide to endometrial cancer signs and symptoms addresses concerns that should be discussed with a clinician.

Getting Your Pathology Reports and Tissue Reviewed in New York

New York Public Health Law 18 governs access to patient information. Subject to its limitations, it provides an opportunity to inspect records within ten days after a written request and requires copies within a reasonable time. Those are different timelines.

Request the original biopsy and surgery reports, all pathology addenda, molecular laboratory reports, and any MLH1 methylation or inherited genetic testing results.

You can begin a legal consultation with a list of providers and approximate dates. You do not need to assemble the entire chart before asking about a filing deadline.

When Missed Molecular Testing May Support a New York Malpractice Claim

A claim generally requires evidence that a provider departed from accepted medical practice and that the departure caused injury. A missing test, an unfavorable outcome, or a different second opinion is not enough on its own.

Current recommendations should not be applied backward as automatic proof of an earlier breach. Nor should molecular testing be assigned one universal date when it supposedly became mandatory.

For represented medical malpractice actions, CPLR 3012-a’s certificate-of-merit provisions ordinarily require the attorney to certify that counsel reviewed the facts, consulted an appropriately knowledgeable licensed physician, and concluded there is a reasonable basis to commence the action.

The statute includes alternatives and exceptions, including a timing provision when an impending deadline prevents obtaining the consultation beforehand.

This is the attorney’s certificate. It is not a physician-signed finding that malpractice has been proved, and it does not replace the evidence needed to establish the claim.

Reviewing a Missed Endometrial Cancer Test or Diagnosis

If your concerns involve a missing molecular report, a pathology interpretation, or a delayed diagnosis, a review should examine what information was available, what care was indicated, and whether an avoidable injury followed.

Porter Law Group represents patients in New York cancer misdiagnosis and delayed-diagnosis matters.

Call 833-888-LATE, email info@porterlawteam.com, or request a free case evaluation. Continue medical follow-up while any legal questions are evaluated.

This article is for informational and educational purposes only. It is not a substitute for medical advice from a qualified healthcare provider or legal advice based on your specific circumstances.

Attorney Advertising. Contacting Porter Law Group does not create an attorney-client relationship.

Frequently Asked Questions

Is molecular classification a screening test for endometrial cancer?

No. Molecular classification evaluates an identified tumor to help characterize its biology and guide care. It does not replace evaluation of abnormal bleeding or other symptoms. Someone without an established cancer diagnosis needs an appropriate diagnostic assessment. Asking for POLE or p53 testing alone does not answer whether cancer is present.

Does an MMRd result mean my children have Lynch syndrome?

No. MMRd describes a feature of the tumor and can have a noninherited cause. Genetic counseling and, when appropriate, germline testing clarify whether you have Lynch syndrome. If an inherited pathogenic variant is confirmed, a genetics professional can explain which relatives should be offered testing and what a result would mean for their care.

Can testing still be considered after my hysterectomy?

Yes. Tumor tissue obtained during surgery may be suitable for molecular testing if enough usable material remains. Your oncologist and pathology laboratory can determine availability and whether additional results would help answer a current treatment or hereditary-risk question. A prior hysterectomy does not itself mean that molecular classification is no longer possible.

Can a molecular test guarantee that a treatment will work?

No. A biomarker may identify a treatment option or help estimate likely benefit, but it cannot guarantee response. Some findings remain uncertain, and tumors can develop treatment resistance. Your oncology team should explain what the result supports, what remains unknown, and how benefits and risks apply to the treatment being proposed.

Can I have a claim if cancer was diagnosed but a test result was missed?

Possibly. A claim can concern treatment after diagnosis as well as the diagnosis itself. The central issues are whether the result should have been obtained or acted on and whether the failure caused injury. Because a treatment-related allegation may follow a different filing analysis from negligent failure to diagnose cancer, request a deadline assessment promptly.